

**In the Claims:**

Please cancel claims 24, 25, and 36-40 without prejudice or disclaimer of the subject matter recited therein.

Please amend the claims as follows:

26. (Amended) An oligonucleotide comprising a sequence selected from:

SEQ. ID NO. 2: 3'-GGTTTGGGTGGAGGTGG-5',  
SEQ. ID NO. 3: 3'-GGAGGTGGTACCCCCCGG-5',  
SEQ. ID NO. 4: 3'-GGTGGTACCCCCCGG-5',  
SEQ. ID NO. 5: 3'-GGAGGTGGTACCCC-5',  
SEQ. ID NO. 6: 3'-AGAAAGAACGAAAGGAA-5',  
SEQ. ID NO. 7: 3'-GGAGGTGGTACC-5',  
SEQ. ID NO. 8: 3'-GGAGCGATGGCTTCCA-5',  
SEQ. ID NO. 9: 3'-AAAGGAACGGGAGCG-5',  
SEQ. ID NO. 10: 3'-GGTCGGTTTGGGTGG-5',  
SEQ. ID NO. 11: 3'-CTTACAGGTCCGTTGA-5',  
SEQ. ID NO. 12: 3'-GGCCGTGTTGCTGT-5',  
SEQ. ID NO. 13: 3'-TCACCCCTCTTTCTGG-5',  
SEQ. ID NO. 14: 3'-GGACACCGACACGG-5',  
SEQ. ID NO. 15: 3'-AACGGGAGCGATGG-5',  
SEQ. ID NO. 16: 3'-ATCTCGGGGTCGTC-5',  
SEQ. ID NO. 17: 3'-AAAGAACGAAAGGAA-5',  
SEQ. ID NO. 19: 3'-CCCGGTACTGA-5', or  
SEQ. ID NO. 20: 3'-CCACAGAAAGAAC-5'.

27. (Amended) An oligonucleotide according to claim 26, wherein the oligonucleotide has one or more modifications.

35. (Amended) The method for inhibiting the expression of tenascin by administering an oligonucleotide according to claim 26.

41. (Amended) A process for the production of a pharmaceutical comprising mixing an efficacious dose of one or more oligonucleotides according to claim 26 with one or more pharmaceutical vehicles and/or additives.

42. (Amended) A process for the preparation of an oligonucleotide according to claim 26, the oligonucleotide being chemically synthesized on a solid phase.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1500 L Street, NW  
Washington, DC 20005  
202.463.4000  
Fax 202.463.4400  
www.finnegan.com